Tenax Therapeutics, Inc.
TENX
$14.66
$0.825.93%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/16/2026
-
MarketBeat
3/13/2026
-
MarketBeat
3/11/2026
-
TipRanks Financial Blog
3/10/2026
-
RTT News - Momentum Stocks
3/10/2026
-
The Fly
3/10/2026
-
Globe Newswire
3/6/2026
-
Zolmax
3/4/2026
-
MarketBeat
3/3/2026
-
Globe Newswire
2/27/2026
-
TipRanks Financial Blog
2/26/2026
-
SeekingAlpha
2/26/2026
-
Seeking Alpha - Healthcare
2/24/2026
-
MarketBeat
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
2/15/2026
-
MarketBeat
2/13/2026
-
Ticker Report
2/13/2026
-
MarketBeat
2/5/2026
-
MarketBeat
2/4/2026
-
Globe Newswire
1/28/2026
-
MarketBeat
1/13/2026
-
MarketBeat
1/10/2026
-
Simply Wall St
1/9/2026
-
TipRanks Financial Blog
1/9/2026
-
Seeking Alpha - Long Ideas
1/9/2026
-
SeekingAlpha
1/8/2026
-
Insider Monkey
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 10, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
919 855 2100
Address
101 Glen Lennox Drive
Chapel Hill, NC 27517
Chapel Hill, NC 27517
Country
Year Founded
Business Description
Sector
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that...
more